Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets

Trial Profile

A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload
  • Focus Adverse reactions
  • Acronyms MIMAS
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Jun 2018 Planned End Date changed from 14 Jan 2020 to 14 Nov 2019.
    • 11 Jun 2018 Planned primary completion date changed from 14 Jan 2020 to 14 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top